2nd Next-Generation Conjugates Summit

The 2^nd Next-Generation Conjugates Summit, designed to help you push the boundaries of bioconjugate drug development with next-generation payloads and formats to improve translation and show a clinical proof-of-concept.

Taking place in Boston in February (21-23), this meeting will serve as a unique touchpoint for developers of next-generation conjugates to learn about cutting-edge technological developments and address key preclinical and translational challenges, and important regulatory and manufacturing bottlenecks to progress to the clinic successfully.

See the complete 2023 event guide here

Our line-up of 20+ industry leading expert speakers includes:

• Vicky Appleman, STING Discovery Lead (Principal Scientist), Takeda Oncology
• James Palacino, Vice President, Head of Biology, Orum Therapeutics
• Oxana Beskrovnaya, Chief Scientific Officer, Dyne Therapeutics
• Hanhua Huang, Vice President, Biology, Avidity Biosciences
• Gavin Bennett, Senior Director, Program Team Leader, Bicycle Therapeutics
• Christian Marsolais, Senior Vice President & Chief Medical Officer, Theratechnologies Inc.
• Hans-Georg Lerchen, Chief Scientific Officer, Vincerx Pharma
• Sukumar Sakamuri, Chief Technology Officer, Aro Biotherapeutics

Find the full list of speakers here

As next-generation conjugates begin to take their place centre stage within the bioconjugate world, learn key lessons from the experience of our experts in order to take your next-generation conjugate from bench to bedside as quickly as possible.

The community looks forward to welcoming you to Boston in February.

The post 2nd Next-Generation Conjugates Summit appeared first on .

manufacturing
therapeutics
medical
pharma